| 规格： | 5mg | 产品价格： | 580 |
|---|
| 规格： | 10mg | 产品价格： | 1080 |
|---|
| 规格： | 50mg | 产品价格： | 2910 |
|---|
Catalog Number GC13296
Molecular Formula C24H25ClFN5O3
Relative Molecular Mass 485.94
CAS Registry Number 439081-18-2
Formulation A solid
Purity ≥98%
Storage Store at -20°C
SMILES CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4
产品描述
Afatinib (BIBW2992), an irreversible inhibitor of the ErbB family of tyrosine kinases, downregulates ErbB signalling by binding to the kinase domains of epidermal growth factor receptor (EGFR)/ human epidermal growth factor receptor 2 (HER2) with IC50 of 0.5 nM and 14nM, respectively. The ErbB receptor tyrosine kinase family consists of four cell surface receptors: ErbB1/ EGFR/HER1, ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4. It has been shown that EGFR and HER2 play important roles in the development and progression of certain aggressive types of cancers and inflammation-associated diseases.Afatinib was shown to suppress EGF-induced phosphorylation of EGFR and cell proliferation in a variety of EGFR-overexpressing and HER2-expressing cell lines such as A431, NIH-3T3-HER2, NCI-N87 and BT-474 [1].The component has also been used extensively in various animal models to study the role of EGFR/HER2. Oral administration of afatinib inhibited cancer cell growth and survival and suppress the tumor regression in xenograft and transgenic lung cancer models [2]. In addition, afatinib is identified as EGFR blocker which was approved for the treatment of patients with EGFR-mutated nonsmall cell lung cancer [3]. References:1.Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008,98:80-85.2.Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008,27:4702-4711.3.Engle JA, Kolesar JM. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. Am J Health Syst Pharm 2014,71:1933-1938.
更多产品信息，请点击：https://www.glpbio.cn/search.php?catalog=GC13296原装进口,Afatinib (BIBW2992),美国GlpBio品Pai大包装更优惠!
美国Glpbio是一家领先的小分子YZ剂、激活剂、化合物库、多肽和实验室试剂的供应商。公司经营范围广泛，产品涉及癌症、免疫学、神经科学、细胞凋亡、表观遗传学等20多个不同研究领域，拥有10000多种产品。总部位于美国加利福尼亚，营销网点遍及法国、德国、加拿大、日本、澳大利亚、新加坡、以色列等20多个国家地区，竭诚为各国的科研工作者提供优质的产品和专业的服务。
温馨提示：不可用于临床ZL。
